Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial

CONCLUSIONS: Our analysis identified ERBB2 copy number as well as 6q23-24 CNAs as predictors of response to anti-HER2-based treatment. ERBB2 expression outperformed ERBB2 amplification. The complexity of the 6q23-24 region warrants further investigation.PMID:34321278 | DOI:10.1158/1078-0432.CCR-21-1317

Source: Clinical Cancer Research - July 29, 2021 Category: Cancer & Oncology Authors: David Venet Mattia Rediti Marion Maetens Debora Fumagalli David N Brown Samira Majjaj Roberto Salgado Lajos Pusztai Nadia Harbeck Sarra El-Abed Yingbo Wang Cristina Saura Henry Gomez Vladimir Semiglazov Evandro de Azambuja Jens Huober Paolo Nuciforo Seren Source Type: research